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Acute myeloid leukemia (AML) is, as other types of cancer, a genetic disorder of somatic
cells. The detection of somatic molecular abnormalities that may cause and maintain AML
is crucial for patient stratiﬁcation. The development of mutation-speciﬁc therapeutic inter-
ventions will hopefully increase cure rates and improve patients’ quality of life.This review
illustrates how next generation sequencing technologies are changing the study of cancer
genomics of adult AML patients.
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Acute myeloid leukemia (AML) is the most frequent hematolog-
ical malignancy in adults, with an estimated worldwide annual
incidence of three to four cases per 100,000 people. Despite inten-
sive research for new therapies and prognostic markers, it is still
a disease with a highly variable prognosis among patients and a
high mortality rate. Indeed, less than 50% of adult AML patients
have a 5-year overall survival rate (OS), and, in the elderly, only
20% survive 2 years (Gregory et al., 2009).
In general, both prognosis and treatment choice for AML
patients are based on the presence or absence of speciﬁc genetic
alterations, which determine AML classiﬁcation in three risk
based-categories: favorable, intermediate, and unfavorable. This
classiﬁcation is usually based on cytogenetic information. AML
with a favorable prognosis includes patients with inv(16) (that
generates the CBFB–MYH11 fusion protein), t(15;17) (that gener-
ates the PML–RARA fusion protein), or t(8;21) (that generates the
AML1–ETO fusion protein). The 5-year OS rate of patients in this
category is 55%. The unfavorable subgroup includes patients with
monosomy 5, monosomy 7, 11q23 (that generates MLL-highly
variable breakpoints on the partner fusion protein), or complex
cytogenetics, and the 5-year OS rate is reduced to 11%. Favor-
able prognosis AML patients are usually treated with primary
chemotherapy, while high-risk patients are considered for allo-
genic stem cell transplantation in ﬁrst remission if a suitable donor
is found. The intermediate subgroup includes normal karyotype
(NK)AML patients. Patients belonging to this group have a 5-year
OS rate ranging between 24 and 42%, depending on the study, but
it is still largely unclear what might be the best therapeutic strategy
for them (Gregory et al., 2009; Tefferi et al., 2009).
More recently, other mutations associated to AML have been
identiﬁed (FLT3, CEBP, NPM1, IDH1/2) and their prognostic
power investigated particularly in the intermediate risk category.
FLT3–ITD and CEBPA mutations seem to associate with a bad
prognosis, while NPM1 and IDH1/2 are controversial. However,
several challenges still lie ahead and markers are needed to predict
prognosis and sensibility to treatment.
Understanding the genetic lesions associated to AML is also
important in order to adjust for speciﬁc therapies. For example,
Acute Promyelocytic Leukemia (APL, one of the AML subtypes) is
treated with a combination of the differentiation-inducing agent
ATRA (all-trans retinoic acid) and chemotherapy, which induces
long-term remissions or cure in 75–85% of patients. Some of the
newly described genetic lesions (e.g., FLT3) may be targeted by
speciﬁc inhibitors which have shown anti-leukemic efﬁcacy in pre-
liminary studies, and are now currently being evaluated in phase
III clinical trials.
The advent of second- (or next) generation sequencing tech-
nologies has dramatically accelerated biological and biomedical
discoveries by enabling comprehensive analysis of genomes, tran-
scriptomes, and DNA–protein interactions. These technologies
allow the identiﬁcation of cancer-associated mutations at a single-
base resolution in an unbiased manner, and will likely revolution-
ize our understanding of cancer. A comprehensive description of
somatic mutations in cancer is essential as it can (i) shed light on
tumor initiation and progression mechanisms, (ii) assist patient
stratiﬁcation for prognosis and treatment choice, and (iii) allow
the identiﬁcation of new genes that can be speciﬁcally targeted by
therapy.
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Massive parallel sequencing is now discovering a growing num-
ber of submicroscopic somatic mutations with prognostic signif-
icance. These, together with the primary somatic genetic abnor-
malities already identiﬁed, are enabling the drawing of patient
mutation proﬁles and will hopefully have a major impact on
the clinical management of AML, not only as independent prog-
nostic factors, but also as the foundation of genome-informed
personalized cancer treatments.
In this review, we will examine the somatic mutations recently
identiﬁed using next generation sequencing (NGS). First, we will
describe which types of mutations can be detected by sequenc-
ing and comment on the pros and cons of different technological
approaches (synthesized in Table 3). Then, we will describe all
the identiﬁed mutations and the subsets of recurring mutations
according to sequencing technology and mutation type (cataloged
in Tables 1 and 2). Finally, we will discuss future perspectives in
the use of NGS technologies in the clinical setting and existing
open challenges.
MASSIVE PARALLEL SEQUENCING APPROACHES FOR
MUTATIONAL ANALYSIS IN AML
To identify AML somatic mutations by NGS, sequencing is usually
performed on DNA or RNA obtained from bone marrow sam-
ples (with high level of tumor cellularity) and normal tissues (skin
biopsies or peripheral blood) from the same AML patient when
in clinical remission. This approach aims to deﬁne somatic vari-
ants, including single nucleotide variants (SNVs), short deletions
and insertions (indels), structural variants (SVs) such as translo-
cations, long insertions or deletions, and copy number variations
(CNVs), which are present in the tumor sample and absent in
the matched control sample. Usually, the sequences from tumor
and normal samples are mapped to the reference genome and the
sequence changes (variants) that differ from the reference genome
are identiﬁed. Variants present in both tumor and control samples
(generally referred to as germline variants) and variants matching
known single nucleotide polymorphisms (SNPs) are discarded.
All the identiﬁed variants are then validated by using an
independent sequencing technology, for example DNA Sanger
sequencing. Finally, the validated variants are usually tested on
a large number of clinical samples, in order to determine their
actual frequency and to identify recurrent mutations.
Currently, there are three experimental approaches, which
are most frequently utilized to identify somatic mutations
by NGS: whole-genome sequencing, exome-sequencing, and
transcriptome-sequencing (also known as RNA-sequencing).
Whole-genome sequencing allows the identiﬁcation of the entire
DNA sequence of a given sample, at single-base resolution level.
Exome-sequencing, instead, is preceded by an exome capture step
that selects the coding regions of the genome (representing ∼1%
of the genome). RNA-sequencing measures the transcriptome.
Sequencing is performed using either single-end or paired-end
tags (PET). In PET, short and paired reads are obtained from
the ends of DNA fragments for sequencing. The use of PET in
genome re-sequencing has advantages over the use of single tags,
as it allows higher mapping speciﬁcity and the identiﬁcation of
small and large insertions, deletions, and translocations, which is
not possible using single-end tags.
The two parameters to take into considerations to understand
data analysis and interpretation are the “coverage” and the “read
lengths.” Coverage is the number of tags aligned to each base of
the reference genome. A high coverage is desired because it can
overcome errors in base calling and assembly, and it can reduce
false positives. Longer read lengths are more easily mapped to the
reference genome, increasing the proportion of the genome that
is mappable. Moreover, longer read lengths are essential for the
detection of small indels.
Each of these techniques has pros and cons (see Table 3).
Whole-genome sequencing allows identiﬁcation of all the possible
variants at once, and it is the best method to study chromo-
somal rearrangements; however, it is expensive ($5000–$15,000
per sample, depending on the sequencing services and cover-
age) and requires a high amount of starting material (usually
1μg of genomic DNA). Exome-sequencing reduces costs ($1000–
$2000 per sample), but not the amount of starting material
(usually around 3 μg of genomic DNA), and allows high cov-
erage in coding regions. Exome-sequencing relies on a capture
step that may not have uniform efﬁciency, and the identiﬁcation
of chromosomal rearrangements is restricted to exonic regions.
RNA-sequencing is capable of detecting variants present in the
transcriptome and fusion genes of expressed genes (Maher et al.,
2009). RNA-sequencing, which necessitates 0.1–4μg of RNA as
starting material, further reduces costs ($300–$500 per sample);
importantly,while allowing identiﬁcation of tumor-speciﬁc fusion
transcripts or mRNA-splice variants, it also offers information on
gene expression levels. There are three main disadvantages, how-
ever, in usingRNA-sequencing to detect somatic variants. First, the
identiﬁcation of the corresponding normal sample is challenging
and, even if one could successfully identify it, gene expression in
cancer cells is altered from that of normal cells. Second, SNVs and
indels within genes that are transcribed at very low levels or in
those for which mutations may induce mRNA degradation may
be missed. Finally, the chance of errors due to reverse transcriptase
and the phenomenon of RNA editing (Li et al., 2011) can make
these data difﬁcult to interpret (Meyerson et al., 2010).
WHOLE-GENOME SEQUENCING
The ﬁrst demonstration of the possibility to identify somatic
mutations in cancer genomes using sequencing technologies was
obtained in a patient with AML (NK, M1 subtype; Ley et al.,
2008). The authors, using single-end whole-genome sequencing,
identiﬁed mutations in the entire genome but decided to vali-
date only those which (i) had occurred in coding sequences, (ii)
were non-synonymous, or (iii) were predicted to alter splicing sites
(all the 181 identiﬁed variants and 28 manually selected indels).
In this ﬁrst study, the percentage of computationally identiﬁed
false positive variants was quite high, since only 5% of the iden-
tiﬁed mutations could be validated. The authors discovered 10
non-synonymous somatic mutations: eight novel SNVs and two
previously described indels (i.e., in NPM1 and FLT3; Table 1).
They sequenced the 8 novel SNVs in 187 additional AML cases
but could not ﬁnd any of these variants.
In the following year, the same group sequenced another patient
with cytogenetically normal AML-M1 (Mardis et al., 2009), using
paired-end whole-genome sequencing. In this second attempt,
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Table 3 | Comparison of pros and cons of whole-genome sequencing, exome-sequencing, and RNA-sequencing.
Characteristics Whole-genome sequencing Exome-sequencing Transcriptome-sequencing
Cost $5000–$15,000 per sample $1000–$2000 per sample The cheapest method: $300–$500 per sample
Starting material 1μg of genomic DNA 3μg of genomic DNA 0.1–4μg of RNA
Detectable variants All possible variants Restricted to exonic regions, hard to identify
structural variants, and copy number variations
Detection of variants present in the transcrip-
tome and fusion genes
Pros Detection of all the possible
variants present in a
genome
Lower cost, greater depth of coverage, and
corresponding improvement in data quality
essential to detect mutations at lower frequency
Identiﬁcation of tumor-speciﬁc fusion tran-
scripts, mRNA-splice variants, and informa-
tion on gene expression levels
Cons Very expensive, so typically
designed with low coverage
Hard to identify structural variants and copy
number alterations
Hard to identify the corresponding normal
samples. Hard to identify SNVs and indels
in transcripts at low expression or for which
mutations may induce mRNA degradation.
Errors due to reverse transcriptase and the
phenomenon of RNA editing can make these
data difﬁcult to interpret
it was decided to validate not only SNVs and indels present in
coding regions and in consensus-splice site regions, but also those
present in non-coding genes, in conserved regions, or in regions
having regulatory potentials. Ultimately, they identiﬁed 7 non-
synonymous SNVs, 1 splice site SNV, 2 indels in coding regions,
and 52 somatic point mutations in conserved or regulatory por-
tions of the genome (Table 1). They tested these mutations in
additional 188 AML samples and found that the mutations on the
IDH1 gene were also present in other AML samples at a frequency
of ∼10% (Table 2). Furthermore, one of the 52 mutations found
in conserved or regulatory portions of the genome was detected
in one additional AML tumor. Previously identiﬁed mutations,
such as NPM1 and NRAS, were also found amongst the mutations
within coding regions.
One year later, the researchers re-sequenced the genome
from the relapsed AML and control samples of the original
patient reported in 2008 (Ley et al., 2008), using paired-end
sequencing in order to obtain a higher depth of coverage (Ley
et al., 2010). They found, among several other non-synonymous
new mutations (not described) a 1-base pair (bp) deletion in
the DNA methyltransferase-3-alpha (DNMT3A) gene (identi-
ﬁed through array-based genomic re-sequencing just few months
before; Yamashita et al., 2010; Table 1). To assess DNMT3A muta-
tion frequency, the authors ampliﬁed and sequenced by Sanger
technique the 24 exons of DNMT3A in 188 additional de novo
AML samples (and their matched normal counterparts) and in
other 93 AML samples (without corresponding normal controls).
They ascertained that DNMT3A variants were present in 62 of
the total 281 AML DNA samples examined (22%), deﬁnitely
proving that DNMT3A is recurrently mutated in AML. All the
variations identiﬁed in the 188 matched-sample validation set
were conﬁrmed to derive from somatic mutational events, since
DNMT3A mutations were not found in the normal sample set.
Two distinctive categories of DNMT3A mutations were found:
highly frequent SNVs, producing variations in the R882 amino
acid residue, and ∼20 other different widely distributed missense
mutations.
From this study, a mutually exclusive relationship was found
betweenDNMT3A mutations and the three classical AML translo-
cations [t(15;17), t(8;21), and inv(16)], which correlate with low
cytogenetic risk. The same had been already observed for muta-
tions ofNPM1, IDH1, and IDH2 that usually donot appear inAML
cells when one of the above-mentioned chromosomal rearrange-
ments is present. However, an association between the DNMT3A
mutation and mutations of these genes, and also FLT3, was shown
very clearly. Co-occurrence of DNMT3A mutations with MLL
genomic variants, present in 11 of the 281 patients examined,
was also never observed. Variations in the DNMT3A genomic
sequence were frequently found enriched in NK samples (44/119
NK samples, 37%). Indeed, the presence of DNMT3A mutations,
concomitantly with variations in FLT3, NPM1, IDH1, and IDH2,
contributed to identify a group of patients that strictly associated
with an intermediate cytogenetic risk, and to speciﬁcally exclude
patients with an adverse prognosis. Finally, DNMT3A mutations
were found associated with poor event-free and overall survival,
regardless of NPM1 status, age, and cytogenetic risk; patients also
carrying FLT3 tandem duplication had a signiﬁcantly worse out-
come. So far, the DNMT3A mutation is the most frequent novel
genomic variation in AMLs identiﬁed and characterized thanks
to the application of massive parallel sequencing technologies
(Table 2).
Welch et al. (2011) have recently described a successful clinical
application of whole genomic sequencing, presenting the case of a
patient with a difﬁcult diagnosis of AML: the patient appeared to
have a hyper-granular APL-like leukemia, but it was impossible to
detect the PML–RARA oncogene by routine cytogenetic proﬁling
or FISH, and PCR was not done. The correct identiﬁcation of an
APL is a critical requirement since APLs are the only AMLs that
can be cured without allogeneic stem cell transplantation. Given
the complexity of this case, the authors decided to apply whole-
genome sequencing to the patient’s leukemia cells (Table 1). This
led to the identiﬁcation of the insertion of a segment of chromo-
some 15 (containing the LOXL1 and PML genes) into the second
intron of RARA on chromosome 17, generating the PML–RARA
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fusion gene and two other fusion genes: LOXL1–PML and RARA–
LOXL1. In the end, the patient was correctly diagnosed with APL
and got into remission after being treatedwithATRA.Thus,whole-
genome sequencing can detect translocations that may be missed
by cytogenetic proﬁling. Indeed, by analyzing 11 other cases of
AML with APL-resembling features, the authors also found that,
in two of these, the PML–RARA fusion gene had derived from
an insertional translocation instead of a translocation. In addi-
tion, Welch and colleagues identiﬁed, in the same tumor sample,
the presence of 12 non-synonymous SNVs, 1 inversion, 2 addi-
tional translocations and 4 deletions. The frequencies of the 12
SNVs were consistent with the presence of two different leukemic
clones.
Finally, Link et al. (2011) identiﬁed a novel cancer susceptibility
gene by sequencing leukemic bone marrow and normal skin sam-
ples from a patient with therapy-related AML and multiple early
onset primary tumors. They detected a germline deletion variant
that had caused the elimination of exons 7–9 of the TP53 gene.
Furthermore, the authors discovered 16 non-synonymous SNVs,
2 variants in splice sites, 2 indels in coding regions, 8 SVs, and 12
somatic copy number alterations (Table 1).
Whole-genome sequencing has been also used to ﬁnd somatic
mutations in mouse models of APL (Wartman et al., 2011). Wart-
man et al., in fact, identiﬁed three somatic non-synonymous SNVs
in leukemia samples from a PML–RAR knock-in mouse (Table 1).
One of the three mutations affected the Jak1 gene and recurred
in 6 of the 89 additionally screened mice. An identical mutation
in the human JAK1 gene had been already described in human
APLs. Furthermore, the authors found a 150-kb somatic deletion
on chromosome X affecting the Kdm6a gene. A similar mutation
was also found in one of the 150 AML patients regarded as the
human leukemia population of comparison.
Development of drug resistance has been linked to hundreds of
gene mutations in experimental models, using in vitro cell lines or
transgenic mice (e.g.,MDR-1). There is no conﬁrmation, however,
of any of them having a speciﬁc role in acquired clinical resistance
following anticancer therapy, or that they can be used as prognos-
tic factors to predict treatment outcome. Thus, the molecular basis
of chemoresistance in human tumors, including AMLs, remains
largely unknown.
Recently, Ding et al. (2012) have reported the whole-genome
analysis of primary/relapse tumor-pairs from 8 AML patients,
using NGS technologies. This is the ﬁrst report of an exten-
sive search of tumor mutations in relapsing tumors. Initially, the
authors analyzed each tumor pair using a sequence protocol that
allows identiﬁcation of high frequency mutations. They used a
sequence coverage of ∼30×, corresponding to low cell detection
sensitivity. With this approach, Ding and colleagues documented
the existence of relapse-speciﬁcmutations in all the analyzed cases.
The authors then looked for the presence of these relapse-speciﬁc
mutations in the primary tumors of origin, using a sequence pro-
tocol that allows identiﬁcation of low-frequency mutations (in
this second phase the sequence coverage was∼500×, which corre-
sponds to a cell detection sensitivity of around 5%). Interestingly,
under these experimental conditions, a few relapse-speciﬁc muta-
tions could be also detected in the respective primary tumors.
These data represent a direct demonstration that chemotherapy
can induce the selection of rare tumor sub-populations harboring
speciﬁc gene mutations (clonal selection). As clonal selection was
not shown in three of the eight analyzed cases but some relapse-
speciﬁc mutations were still found, alternative mechanisms of
chemoresistance might have been present in these patients (the
mutation could have been acquired during treatment). On the
other hand, they might have been already present in the primary
tumor, but had escaped identiﬁcation due to the limited sensitiv-
ity of the detection assay (∼5%). Regrettably, the authors did not
investigate whether the identiﬁed relapse-speciﬁc mutations were
indeed responsible of the chemoresistance (i.e., whether they were
chemoresistance-speciﬁc mutations). This study identiﬁed a total
of 141 mutated genes present in primary AML, of which 129 were
novel mutations in AML. Using 200 AML cases whose exomes
were sequenced as part of the Cancer Genome Atlas AML project,
Ding et al. identiﬁed 126 of the 129 novel mutations in other AML
samples.
EXOME-SEQUENCING
Most whole-genome sequencing analyses only focused on variants
present in coding regions, as mutations in the coded portion of the
genome are easier to interpret because of their putative impact on
protein functions. This approach, although restrictive, has been
nevertheless successful allowing the identiﬁcation of many novel
mutations. Since the publication of the ﬁrst exome-sequencing
study in 2009 (Ng et al., 2009), many groups have been report-
ing the use of exome-sequencing to identify mutations present in
cancer or in other pathological conditions (Meyerson et al., 2010;
Singleton,2011 for reviews).Novelmutations identiﬁedby exome-
sequencing in AML (Grossmann et al., 2011; Yan et al., 2011) and
APL (Greif et al., 2011a) patients have been also recently published.
Yan et al. (2011) published exome-sequencing data from bone
marrow and control tissues derived from nine patients with AML-
M5. They validated 58 SNVs and 8 indels with Sanger sequencing,
identifying 66 somatic mutations in 63 genes (Table 1). These
somatic mutations included known variants (e.g., in NRAS and in
FLT3) as well as theMLL–MLLT4 fusion gene.Other ﬁveAML-M5
cases without matched normal samples were sequenced and the
authors focused on additional mutations occurring in the 63 iden-
tiﬁed genes. Furthermore, the authors checked all the sequence
changes detected in the 63 genes in other 98 AML-M5 leukemia
samples (94 newly diagnosed and 4 relapsed); these variants were
not present in the control set, consisting of 509 normal samples
from healthy donors, or in the matched control samples. In total
112 samples were tested and amongst these 14 genes weremutated,
each in at least 2 of the 112 cases. Yan and colleagues selected 5 of
these 14 genes (DNMT3A,ATP2A,C10orf2,CCND3,GATA2) plus
a genemutated only in one case (NSD1) and sequenced their entire
coding regions in the 98 AML-M5 leukemia samples, discovering
three different DNMT3A variants in ∼20% of the samples. Inter-
estingly, they observed that individuals with DNMT3A mutations
had aworse prognosis than thosewithout and that thesemutations
were common in elderly patients.
Toﬁnd cooperativemutations inAPL,Greif et al. (2011a) exam-
ined the exome-sequencing data of threeAPL patients who did not
have mutations in FLT3. After the exclusion of annotated poly-
morphisms, the authors conﬁrmed a total of 12 non-synonymous
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SNVs and 1 indel in coding regions (Table 1). The identiﬁed
mutations (including known mutations such as WT1 and NRAS)
did not overlap in the three APL patients, suggesting that the spec-
trum of mutations that can cooperate with PML–RARA might be
large and diverse.
NPM1 and CEBPA mutations are found in 60% of NK AML
cases, but the remaining 40% are not well characterized. To bet-
ter characterize this second group of AMLs, Grossmann et al.
(2011) sequenced a NK AML case with no mutations of the
NPM1, CEBPA, FLT3–ITD, or MLL gene and identiﬁed 12 non-
synonymous SNVs and 1 frame-shift deletion, corresponding to 11
distinct genes (Table 1). All these mutations were found to be het-
erozygous. The authors selected 4 of these 11 genes (BCOR, YY2,
SSRP1, and DNMT3A) and performed deep-sequencing analysis
of all their exons in other AML patients who had a karyotype sim-
ilar to their original AML case (i.e., a NK in the absence of NPM1,
CEBPA, FLT3–ITD mutations, and MLL partial tandem dupli-
cation, PTD). They found that one case (1/16; 6.25%) carried a
mutation in the SSRP1 gene, 4 (4/30; 13.3%) in DNMT3A and 5
(5/30; 16.6%) in BCOR. BCOR frequency was conﬁrmed in a total
of 82 NK cases with the above genetic features (14/82; 17%). In
a second phase of the study, to assess the real frequency of BCOR
mutations in unselected patients with NKAMLs,Grossmann et al.
analyzed 262 unselected NK AML patients from an independent
Italian cohort characterized for mutations in NPM1, FLT3–ITD,
and DNMT3A. They found BCOR mutations in 10/262 (3.8%)
cases; all these patients had a karyotype similar to their initial index
patient. ThusBCOR mutations appear to bemostly enriched in the
least characterized subgroup of NK AML, the subgroup with wild
type NPM1, FLT3–ITD, IDH1, and MLL genes. The authors also
studied the frequency of BCOR mutations in 131 AML patients
with cytogenetic abnormalities but no mutation was found. Inter-
estingly, BCOR mutations were usually associated with DMNT3A
and only rarely with NPM1; ﬁnally, for NK leukemias, mutation
of the BCOR gene appeared associated with a worse outcome.
TRANSCRIPTOME-SEQUENCING
Greif et al. (2011b) had shown that transcriptome-sequencing by
RNA-seq could also be used to identify recurrent or rare muta-
tions in leukemia. A bonemarrow sample (≥90% cellularity) from
an NK AML patient and a normal sample from the peripheral
blood of the samepatientwere compared byRNA-seq. Five tumor-
speciﬁc SNVs (inRUNX1,TLE4,SHKBP1,XPO7, andRRP8 genes)
were identiﬁed and validated (Table 1). Except for the mutation
in the RUNX1 gene, a known recurrent mutation in AML, the
other four were novel mutations. Variants in TLE4 and SHKBP1
were considered potentially relevant for further characterizations.
TLE4, in fact, had been previously identiﬁed as a putative tumor
suppressor and a possible cooperative gene of AML1–ETO inAML
patients with chromosome 9q deletions (Dayyani et al., 2008).
SHKBP1, on the other hand, is putatively linked to leukemia
through the interaction with SETA which mediates its binding
to CBL, an ubiquitin ligase involved in the degradation of FLT3.
To evaluate the frequency of these mutations, the authors re-
sequenced the coding sequence for bothTLE4 and SHKBP1, aswell
as for RUNX1, in 95 additionally NK AML patients. The authors
found two missense mutations (2%) for TLE4 and SHKBP1 and
nine missense mutations (9.5%) for RUNX1. Notably, RUNX1,
TLE4, and SHKBP1 mutations were mutually exclusive; moreover,
TLE4 was found in samples carrying NPM1 and CEBPA variants,
whereas SHKBP1 was found in combination withNMP1 and FLT3
mutations. To date, this is the only high-throughput experiment
that has studied AML by RNA-seq.
Small non-coding RNAs play a key role in regulating a large
variety of biological processes, including tumorigenesis. Thus, it is
expected that they will be affected by mutations, like their cognate
“coding genes.” In a recently published genome wide analysis of
microRNAs (miRNAs; Ramsingh et al., 2010), the authors applied
NGS technologies to the characterization of the microRNAome in
a sample from the same AML patient previously studied in 2008
(Ley et al., 2008). They looked for miRNA mutations, aberrant
expression, and miRNA binding-site mutations, detecting several
new miRNAs (some of them expressed differently in the tumor
and control samples), no somatic mutations of miRNA genes,
and one somatic mutation in the 3′-UTR of the TNFAINP2 gene,
which may result in the acquisition of a novel miRNA binding-
site (Table 1). However, this gene was not mutated in 187 de novo
AMLs, suggesting that this mutation is rare in primary AMLs.
Likewise, no somatic mutations of miRNA genes were identiﬁed
in this leukemic genome.
GENOMICS OF MYELODYSPLASTIC SYNDROMES BY NGS
Together with AMLs, myelodysplastic syndromes (MDSs), and
myeloproliferative neoplasms (MPNs) include the majority of
myeloid malignancies. Thus, it is worth mentioning some muta-
tions recently identiﬁed with NGS technologies in these patholo-
gies in relation to AML mutations.
Myelodysplastic syndromes represent a heterogeneous group
of clonal hemopathies, characterized by bone marrow dysplasia,
aberrant differentiation, peripheral cytopenia, increased incidence
in old age and risk of progression to AML. At the end of 2011,
four signiﬁcant papers described speciﬁc mutations identiﬁed in
MDSs by exome and whole-genome sequencing (Papaemmanuil
et al., 2011; Visconte et al., 2011; Yoshida et al., 2011; Graubert
et al., 2012). These recent publications, as well as corollary papers
published soon after (Malcovati et al., 2011; Makishima et al.,
2012) clearly indicate that, besides karyotypic abnormalities (i.e.,
5q−, −7/7q−, trisomy 8, 20q−, and −Y) and “prototypic” gene
mutations (e.g.,TET2,RUNX1,TP53,ASXL1,NRAS/KRAS,EZH2,
JAK2, andMPL),which had been linked to MDS for years, compo-
nents of the splicing machinery are recurrent targets of mutations
in MDSs and in myelodysplasia (e.g., U2AF1/U2AF35, SRSF2,
ZRSR2, SF3B1, SF3A1). In particular, surprisingly high mutation
frequencies (20–85%) were reported in the SF3B1 gene (Papaem-
manuil et al., 2011; Visconte et al., 2011; Yoshida et al., 2011;
Makishima et al., 2012); thesewere almost speciﬁc to theMDS sub-
types refractory anemia with ring sideroblast (RARS) and RARS
associated with marked Thrombocytosis (RARS-T), suggesting
that they might be virtually pathognomonic to these MDS groups.
Little overlap was observed between SF3B1 and all the other
mutations identiﬁed in genes of the spliceosome complex and
those found so far in AML (Table S1 in Supplementary Material),
suggesting that these splicing pattern mutations have a distinctive
association with the pathogenesis of MDSs. Notably, 3 out of the
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57 AML samples (5.3%) from a 2087 patient cohort screened for
target re-sequencing were reported to contain SF3B1 mutations
(Papaemmanuil et al., 2011); however, this is the ﬁrst report of
SF3B1 mutations in primary AML (even from larger cohorts), and
it is possible that the AML in these three patients derives from the
evolution of a preexisting MDS. This is indeed the case for the two
AML patients (2/38) carrying a somatic SF3B1 mutation in the
study of Malcovati et al. (2011).
Interestingly, Graubert et al. (2012) work examined directly
the genetics of MDS when it evolves into secondary AML (sAML),
studying, by whole-genome sequencing, a sAML patient sample
and then genotyping the identiﬁed mutations in the matched
MDS sample. The authors identiﬁed, among others, a missense
mutation in the U2AF1/U2AF35 gene, an auxiliary factor of the
U2 splicing complex; in 150 additional MDS de novo samples, this
mutation had a frequency of 8.7%. In contrast to SF3B1mutations
that were associated with a relatively benign prognosis, mutations
of the U2AF1/U2AF35 gene were associated with shorter survival
and with an increased risk of developing sAML.
Further studies are needed; however, these results seem to sug-
gest that even if AML and MDS mutation patterns overall share
only few common mutated genes (16/290 AML mutated targets,
Table S1 in Supplementary Material), this number is not expected
to occur simply by chance (Fisher’s exact test P-value= 0.0045).
Even more interesting, 6 of those 16 mutated genes belong to
a group of 10 recurrent mutated genes found in AML (Fisher’s
exact test P-value= 1.3e−09), suggesting that a selected fraction
of recurrent mutations are involved in bothAML and MDS patho-
genesis. Thus genome sequencing of larger collections of samples
may provide new insights into the molecular basis of MDS clinical
heterogeneity and lead to the identiﬁcation of syndrome subtypes
with similar outcomes, e.g., AML progression and/or responses to
therapy.
RECURRING SOMATIC MUTATIONS IN AML: THE STATE OF
THE ART
The NGS studies described so far, led to the identiﬁcation of 281
mutated genes in AML. Among them, 164 have been found in at
least 2 AML patients (Table S1 in Supplementary Material), and
only 10 are recurrent, i.e., they have a frequency higher than 5%
and are found in more than 100 patients (Table 2). Notably, only
16 (∼6%) of the mutated genes were previously known, demon-
strating how powerful NGS technologies can be for the discovery
of AML-associated mutations.
Analysis of the prevalence of these mutations, however, reveals
that 153 of the 265 novel mutations (∼58%) are found in at least
two AML patients (Table S1 in Supplementary Material). Notably,
most of them (149/153, 97%) have a frequency lower than 5%
in AMLs. Thus, these data suggest the existence of two classes of
mutated genes in AMLs: one comprising few (10/281, 3.6%) and
frequently mutated genes, and the other comprising a larger set
of genes with very low mutation frequencies. Although these are
partial data, as these mutations need to be conﬁrmed in a larger
number of samples, known recurrentmutations appear to be over-
represented in the data-set of AML-associated mutations (Fisher’s
exact test P-value= 2.3e−06), suggesting that NGS major contri-
bution to AML cancer genomics will probably be the detection
of rare mutations (with a frequency lower than 5%). Yet, this
might turn out to be a critical step for the identiﬁcation of novel
prognostic or therapeutic targets in AMLs.
In AMLs, much evidence suggests that primary translocations
[inv(16); t(15;17); t(8;21); and 11q23 translocations] are sufﬁ-
cient to initiate leukemogenesis (initiating mutations), yet other
genetic alterations are needed for the selection of the full leukemia-
phenotype (cooperating mutations). In fact: (i) these primary
translocations are frequently found as the only cytogenetic abnor-
mality in AML blasts; (ii) the expression of the associated fusion
proteins induces a pre-leukemic state in mice; (iii) the murine
leukemias that eventually develop have morphological and clini-
cal properties that are near-identical to those of the corresponding
human leukemias. Thus, in AMLs with primary translocations,
NGS might allow identiﬁcation of mutations that cooperate with
fusion proteins to determine the leukemia-phenotype.
Genomic analyses are available for six AML cases with primary
translocations (ﬁve human APLs and one mouse APL; Table 1).
Notably, the frequency of recurrent mutations in these cases is
also extremely low (in total, 42 novel mutations were identi-
ﬁed but none had a frequency higher than 5%), suggesting that
myeloid leukemogenesis may initiate from the alteration of a
few genetic pathways to then proceed through the alterations
of many.
A similar scenario might apply to AMLs with a NK (78% of
all sequenced cases). Mutations of NPM1 are found in ∼25% NK
AMLs, are frequently associated with mutations of other recur-
rently mutated genes, such as FLT3, and never found together with
primary translocations. Notably, as for the AML-associated fusion
proteins, expression of mutantNPM1 inmice induces either a pre-
leukemic state (Cheng et al., 2010, our unpublished data) or the
occurrence of a frank leukemia, after a long (if expressed alone) or
short (if co-expressed with others cooperative mutations) latency
(Vassiliou et al., 2011, our unpublished data). Similarly to AMLs
with primary translocations, AMLs with mutated NPM1 were
found associated with 34 novel non-recurrent mutated genes by
NGS. Thus, NGS might contribute to identify cooperating muta-
tions in AMLs. Functional analyses of these mutations might
then lead to the identiﬁcation of cellular pathways that are crit-
ical for the selection of the leukemia-phenotype, providing a
biological classiﬁcation of leukemias, regardless of the initiating
genetic event.
MOLECULAR AND FUNCTIONAL CONSEQUENCES OF
MUTATIONS IN RECURRENTLY TARGETED GENES IN AML
To derive information about the molecular and patho-functional
impact of mutations directly from the type of mutation and
from their location is always a not-trivial mission. In general, it
might be true that when a genetic variant is found persistently
located at a single amino acid position, the lesion may trigger a
gain-of-function deleteriousmechanism,as already established for
known oncogenic mutations (e.g.,RAS, NPM1). Loss-of-function
is instead suggested by the ﬁnding of widely distributed divergent
mutations along the structure of the gene, as often observed for
several classical tumor suppressor genes (e.g., BRCA1 and TP53).
Actually, often, “hot spot” and dispersed mutations can be both
found in the same gene,making a prediction more difﬁcult. This is
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the case of DNMT3A, the DNA (cytosine-5-)-methyltransferase-
3-alpha, one of the most interesting newly identiﬁed recurrent
targets of mutations in AML.
DNMT3A is an epigenetic modifying-enzyme known to be
essential, together with DNMT3B, for the proper de novo methyla-
tion of DNA. It is one of the novel, most frequently mutated genes
found in AML patients (DNMT3A mutation frequency: ∼20%)
and it is one of those also discovered to be recurrently mutated in
MDS (about 8%; Walter et al., 2011). Its mutated form in AML
(i) is associated with mutations of NPM1, FLT3, IDH1, and CBPA,
(ii) never appears in AML characterized by translocation events,
(iii) is prevalent in AML with NK, and (iv) is associated with poor
survival.
Nearly half of the mutations in the DNMT3A gene are con-
centrated in positions affecting arginine 882 (R882), a conserved
residue of the methyltransferase (MT) domain. The remaining
variations aremore largely distributed along the length of the gene,
although preferentially targeting the MT domain, as well. This
structural observation suggests a loss-of-function mechanism. In
support of this hypothesis, in vitro experiments showed thatmuta-
tions in the DNMT3A MT domain decrease the methyltransferase
activity of DNMT3A. In contrast, overexpression of DNMT3A in
PML–RARA expressing mice recently demonstrated the potential
cooperative nature of DNMT3A to induce APL (Subramanyam
et al., 2010). Indeed, transplantation into irradiated mice of PML–
RARA+/DNMT3A+ bone marrow cells induced leukemia with
shorter latency and higher penetrance than transplantation of
cells only expressing the initiating protein PML–RARA, thus sug-
gesting a gain-on-function mechanism, possibly combined with
a dominant negative effect on the wild type proteins. Interest-
ingly DNMT3A mutations, although not dramatically altering
global DNA methylation levels in AML genomes, tend to pro-
duce modiﬁed methylation patterns in the proximity of speciﬁc
DNA regions and genes (Ley et al., 2010). Further experiments are
required to completely clarify mechanisms and roles of DNMT3A
and its association with co-occurring recurrent and rare genomic
alterations.
FUTURE PROSPECTIVE AND OPEN CHALLENGES
So far, tumor and control samples from 26 AML patients have
been sequenced but larger numbers of samples are expected to be
sequenced in the near future. These data will be crucial to dis-
sect the complexity of somatic mutations, which contribute to
AML pathogenesis. No doubt, NGS platforms will be also further
employed for the discovery of mutations inmousemodels of AML.
The last 3 years, characterized by increased NSG applications,
have seen a dramatic reduction in the costs of data generation,
an increase in coverage, and improvements in computational
data analysis. Indeed, the number of validated mutations of the
computationally predicted variants ranges from 5% (Ley et al.,
2008) to 98% (Yan et al., 2011), thus reducing validation costs
and increasing the automation of the identiﬁcation processes.
Cost reduction, increase in automation, availability of NGS in
medium and small centers, and the possibility to simultane-
ously detect all the genetic variants existing in a cancer genome,
have opened new opportunities for the employment of NGS in
clinical settings.
Three main challenges remain to be addressed. First, while
these technologies can detect many somatic mutations in each
patient, only a subset of them is probably involved in cancer ini-
tiation and progression. Thus, it is essential to develop methods
to distinguish between passenger and driver mutations (Stratton
et al., 2009). Second, an increasing number of mutations have been
identiﬁed in AML. What links these genetic alterations to cancer
progression? What complex interactions underlie AML pathogen-
esis? Third, the use of massive parallel sequencing has also found a
rewarding application in the identiﬁcation of chromatin features;
the next challenge will be to integrate AML genomic information
with AML epigenomic proﬁles.
Help will come from the genome sequencing of 500 de novo
AML cases by the TCGA (http://tcga-data.nci.nih.gov/tcga), an
NIH consortium which aims to contribute to the understand-
ing of the molecular basis of cancer through the gathering
and analysis of different high-throughput data, such as DNA-
sequencing, methylation, gene expression and miRNA expression
data. We foresee different ways of interpreting the huge amount of
information generated by cancer re-sequencing projects in order
to link mutations identiﬁed by NGS technologies to leukemia
progression.
To correlate cancer mutated genes to cancer behavior we will
need to discriminate, within all the variants found in the sequenc-
ing projects, between passenger and driver mutations. Currently,
the deﬁnition of driver mutations is usually based on mutation
frequency (Wood et al., 2007), and mutations are deﬁned as dri-
vers when found in a larger number of AML genomes. Since many
driver mutations may be infrequent and contributing to cancer
development only in few tumors, we will need to test a large
number of tumor samples in order to discriminate between rare
drivermutations andpassengermutations.Anyway, there are other
purely computational ways to identify driver mutations, indepen-
dent of the evaluation of mutation frequency. These methods
can identify driver mutations among those that cause changing
in the amino acid sequence of the associated protein. Methods
as SIFT (Kumar et al., 2009) and PolyPhen-2 (Adzhubei et al.,
2010) can predict for each non-synonymous mutation the impact
of the amino acid substitution on protein structure and func-
tions, using different features such as sequence homology, amino
acid physicochemical properties and protein structure-based fea-
tures. Recently, new methods that use network-based approaches
(Torkamani and Schork, 2009; Cerami et al., 2010; Vandin et al.,
2011) or machine learning algorithms (Carter et al., 2009) have
been developed to identify driver mutations.
However, since the vast majority of somatic mutations are
shared only between few patients, it might be more important
to identify driver pathways rather than driver mutations. Indeed,
driver pathways can be reconstructed using network models con-
taining driver mutations and other genes that may link them
(Vandin et al., 2012). The identiﬁcation of driver pathways is
important to rationalize targets for therapeutic intervention.Many
recentworks identify driver pathways by integrating different types
of high-throughput data, such as copy number variant data and
mRNAexpression data, to identify driverCNVs, to stratify patients
and to obtain mechanistic and prognostic insights (Akavia et al.,
2010; Vaske et al., 2010; Jörnsten et al., 2011).
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Lastly, it is possible to correlate speciﬁcmutations found in very
large collections of patient samples with clinical outcomes, using
unsupervised and supervisedmachine learningmethods.With the
unsupervised methods it is possible to cluster the mutational pro-
ﬁles of different patients to identify common alterations. With the
supervised methods we can identify the features (or biomarkers)
that can better classify speciﬁc subgroups of AML.
In order to determine what most likely drives AML, in addition
to the development of computational methods that can priori-
tize candidate mutations, we will need to functionally characterize
these mutated genes, using in vitro and/or in vivo experiments.
The possibility of recognizing a subset of genetic variations
with predictive and prognostic value will pave the way to a
mutation-speciﬁc, “personalized,” therapy choice. The molecular
classiﬁcation of AML patients will improve clinical outcome and
be essential for disease monitoring. We expect that in a not so
distant future, testing the presence of mutated genes in biopsies
before treatment will become clinical routine practice.
So far studies have focused on the identiﬁcation of mutations
that are present in the majority of tumor cells. Indeed, these works
have identiﬁed mutations with a frequency usually higher than
25%. If we increase the coverage, and we improve bioinformat-
ics pipelines, we could aim to identify small sub-clones (<1%).
Such an achievement could help addressing many important open
questions such as the clonal evolution of tumors and, of clinical
interest, the prediction of resistance to anti-tumoral treatments.
Indeed, Ding et al. (2012) observed changes in mutant allele fre-
quencies between the primary tumor and the relapse tumor, as
well as clonal evolution in 5/8 patients, suggesting that a popula-
tion with potentially chemo-resistant mutations might pre-exist
and expand after treatment.
“MUTATIONS” GLOSSARY BOX
Genomic mutations, genetic variants, genomic alterations, or sim-
ply mutations or variants: they are all synonyms indicating varia-
tions found in the DNA sequence derived from an individual with
respect to the “Reference genome sequence.”
Mutations can be germline or somatic. A “germline mutation”
gives rise to a mutation in the offspring; it is present in every
cell. SNPs belong to this class. A “somatic mutation” or “somatic
variant” is a mutation acquired during the life span of an indi-
vidual in a speciﬁc area of the body (e.g., bone marrow); the cell
where the somaticmutation occurs,may give rise to a clonal prolif-
eration event. A somatic variant can be easily distinguished from
a germline one by comparing the region of the mutated DNA
sequence with a corresponding sequence obtained from another
tissue of the same individual: in the ﬁrst case the sequences will
be different, in the second identical. Both germline and somatic
mutations can be neutral (i.e., do not produce an observable
pathological phenotype) or deleterious (i.e., are directly respon-
sible or contribute to establish a perturbed unhealthy condition).
Neutrality and deleteriousness are not always obvious, but can be
predicted based on the features of the speciﬁc areas of genomic
DNA, such as coding and regulatory potential or involvement in
splicing mechanisms.
Recurrentmutation: it generally indicates that the same somatic
mutation is found in different individuals, usually carrying a
tumor of the same type. Herein, a recurrent mutation is deﬁned
as found in “at least 5% of the tested samples.” Since the chance
of ﬁnding a recurrent event is very low, it likely reﬂects the impor-
tance that a somatic mutation may have on a tumorigenic or
disease predisposing phenotype.
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